Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca MYSTIC Read-Out Delay Further Boost To Merck

Executive Summary

Overall survival data are now not due until the second half of the year but however they turn out competitor Merck & Co is still expected to dominate the late-stage NSCLC market with Keytruda.


Related Content

ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts